Free tool
FAERS Monitor: Leuprolide Acetate For Depot Suspension
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205054 or its brand name (Leuprolide Acetate For Depot Suspension, Leuprolide Acetate). Reports on generic versions are filed under their own applications.
Reports
7,124
Serious
6,163
87% of reports
Hospitalization
2,999
Death reported
1,141
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue407
- drug ineffective377
- off label use326
- hot flush312
- fall283
- asthenia279
- death274
- pneumonia248
- prostate cancer237
- nausea236
- anaemia224
- diarrhoea207
- diabetes mellitus194
- prostatic specific antigen increased194
- headache187
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 96 |
| 2006 | 85 |
| 2007 | 119 |
| 2008 | 351 |
| 2009 | 153 |
| 2010 | 237 |
| 2011 | 236 |
| 2012 | 308 |
| 2013 | 74 |
| 2014 | 72 |
| 2015 | 207 |
| 2016 | 125 |
| 2017 | 135 |
| 2018 | 158 |
| 2019 | 165 |
| 2020 | 205 |
| 2021 | 455 |
| 2022 | 773 |
| 2023 | 781 |
| 2024 | 734 |
| 2025 | 838 |
| 2026 | 734 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,035 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prostatic specific antigen increasedSignal | 194 | 42.2 | 36.7 | 7,649 |
| hot flushSignal | 312 | 12.3 | 11.0 | 3,216 |
| prostate cancerSignal | 237 | 8.7 | 7.7 | 1,614 |
| diabetes mellitusSignal | 194 | 7.5 | 6.6 | 1,093 |
| anaemiaSignal | 224 | 3.5 | 3.1 | 395 |
| fallSignal | 283 | 2.5 | 2.2 | 260 |
| pneumoniaSignal | 248 | 2.3 | 2.0 | 176 |
| astheniaSignal | 279 | 2.2 | 2.0 | 183 |
| fatigue | 407 | 1.5 | 1.4 | 80 |
| off label use | 326 | 1.1 | 1.0 | 3 |
| diarrhoea | 207 | 0.9 | 0.8 | 1 |
| death | 274 | 0.9 | 0.8 | 1 |
| headache | 187 | 0.9 | 0.8 | 3 |
| nausea | 236 | 0.9 | 0.8 | 4 |
| drug ineffective | 377 | 0.8 | 0.8 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.